Phase I study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and immunogenicity.

Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88.

Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients.

A First-in-Human Study To Assess the Safety and Pharmacokinetics of Monoclonal Antibodies against Human Cytomegalovirus in Healthy Volunteers.

Development of human monoclonal antibodies against human cytomegalovirus.

A Novel Monoclonal Antibody Against Human DAB2IP.

Pharmacokinetics and immunogenicity investigation of a human anti-interleukin-17 monoclonal antibody in non-naïve cynomolgus monkeys.

One Against All: A Broadly Influenza Neutralizing Man-made Monoclonal Antibody Passes Phase I.

Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients.

Antibody-mediated response of NKG2Cbright NK cells against human cytomegalovirus.

A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.

Development of novel monoclonal antibodies against starch and ulvan - implications for antibody production against polysaccharides with limited immunogenicity.

A broadly neutralizing human monoclonal antibody is effective against H7N9.

Monoclonal Antibodies Against Human Cardiac Troponin I for Immunoassays II.

Crystallization of the Fab from a human monoclonal antibody against gp 41 of human immunodeficiency virus type I.

Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.

First-in-Man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin.

55.

Human IgM monoclonal antibody 16.88: pharmacokinetics and distribution in mouse and man.

Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors.

Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer.

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.

Monoclonal antibody against ependymoma-derived cell line.

A monoclonal antibody that neutralizes Epstein-Barr virus, human cytomegalovirus, human herpesvirus 6, and bacteriophage T4 DNA polymerases.

Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma.

Suggest Documents

Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88.

Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients.

A First-in-Human Study To Assess the Safety and Pharmacokinetics of Monoclonal Antibodies against Human Cytomegalovirus in Healthy Volunteers.

Development of human monoclonal antibodies against human cytomegalovirus.

A Novel Monoclonal Antibody Against Human DAB2IP.

Pharmacokinetics and immunogenicity investigation of a human anti-interleukin-17 monoclonal antibody in non-naïve cynomolgus monkeys.

One Against All: A Broadly Influenza Neutralizing Man-made Monoclonal Antibody Passes Phase I.

Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients.

Antibody-mediated response of NKG2Cbright NK cells against human cytomegalovirus.

A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.

Development of novel monoclonal antibodies against starch and ulvan - implications for antibody production against polysaccharides with limited immunogenicity.

A broadly neutralizing human monoclonal antibody is effective against H7N9.

Monoclonal Antibodies Against Human Cardiac Troponin I for Immunoassays II.

Crystallization of the Fab from a human monoclonal antibody against gp 41 of human immunodeficiency virus type I.

Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.

First-in-Man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin.

55.

Human IgM monoclonal antibody 16.88: pharmacokinetics and distribution in mouse and man.

Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors.

Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer.

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.

Monoclonal antibody against ependymoma-derived cell line.

A monoclonal antibody that neutralizes Epstein-Barr virus, human cytomegalovirus, human herpesvirus 6, and bacteriophage T4 DNA polymerases.

Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma.

Phase I study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and immunogenicity.

Recommend Documents

Follow Us